Eledon Pharmaceuticals Enters New Era in Transplant Care: Promising Data & Strategic Momentum
Eledon Pharmaceuticals (NASDAQ: ELDN) gains momentum with promising Phase 1b results, strong financials, and a bold mission to redefine transplant medicine with its lead candidate, tegoprubart.
→ See More